We are honored to have been selected as a partner to the FamilieSCN2A Foundation and to support their work to improving the lives of individuals affected by SCN2A-related disorders by accelerating the development of precision therapies for these disorders.
At Cellectricon, we solve our Clients’ scientific challenges through innovative approaches for in vitro research. Under this collaboration, we will apply our advanced neuronal assay technologies to explore how SCN2A variants impact neuronal activity in human stem cell-derived neurons. Ultimately, the project aims to develop and validate a standardized screening assay that can be used by researchers and pharmaceutical companies worldwide to develop treatments for SCN2A-related disorders.
If you are curious to learn more about how we can support your drug discovery project, please get in touch.